American journal of ophthalmology · 2007
Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amselem Luis, Montero Javier, Diaz-Llopis Manuel, Pulido Jose S, Bakri Sophie J, Palomares Paula, Garcia-Delpech Salvador
Аннотация
PURPOSE: To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS).
DESIGN: Interventional case reports.
METHODS: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications.
RESULTS: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present.
CONCLUSIONS: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.
DESIGN: Interventional case reports.
METHODS: Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications.
RESULTS: One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present.
CONCLUSIONS: Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.
Предметные рубрики MeSH
AgedAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabFluorescein AngiographyHumansInjectionsIntraocular PressureIrisIschemiaMacular EdemaMaleNeovascularization, PathologicSyndromeTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityVitreous Body